Price Vision Group
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Inclusion Criteria: * 18 years of age or older * With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids. * Signed written informed consent. Exclusion Criteria: * Known sensitivity to treatment medications * Current condition that in the investigator's opinion could compromi…
Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
Arctuva estimate
Verify or correct the compensation shown for this listing.